^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vegzelma (bevacizumab-adcd)

    i
    Other names: CT-P16
    Company:
    Celltrion
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    22d
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Merck Sharp & Dohme LLC | N=78 --> 280
    Enrollment change
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)
    2ms
    NCI-2018-01503: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    MSLN (Mesothelin)
    |
    Avastin (bevacizumab) • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • anetumab ravtansine (BAY 94-9343)
    2ms
    A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (clinicaltrials.gov)
    P1, N=90, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2029 --> May 2030 | Trial primary completion date: Jul 2028 --> May 2030
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc) • Vegzelma (bevacizumab-adcd)
    2ms
    CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=454, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Sep 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2ms
    Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Mayo Clinic | N=54 --> 85
    Enrollment change • Checkpoint inhibition
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • tiragolumab (RG6058)
    3ms
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3ms
    Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov)
    P3, N=252, Not yet recruiting, NRG Oncology
    New P3 trial
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3ms
    Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (clinicaltrials.gov)
    P3, N=120, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • fluorouracil topical
    4ms
    External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    7ms
    NRG-GY036: Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (clinicaltrials.gov)
    P3, N=880, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting | Trial completion date: Dec 2035 --> Dec 2034
    Enrollment open • Trial completion date
    |
    BRCA (Breast cancer early onset)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    7ms
    External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2031 --> Jan 2032 | Initiation date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2030 --> Jan 2031
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)